Trial Profile

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPK 88004 (Primary)
Indications Prostate cancer
Focus Therapeutic Use
Acronyms SARM-PC

Most Recent Events

12 May 2021 Results assessing safety and efficacy of OPK-88004 in symptomatic, testosterone-deficient men who had undergone radical prostatectomy for low grade, organ-confined prostate cancer, published in the Journal of Clinical Endocrinology and Metabolism.
04 Mar 2020 Status changed from active, no longer recruiting to completed.
05 Nov 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com